NurExone Biologic Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 3.64 million compared to USD 8.17 million a year ago. Basic loss per share from continuing operations was USD 0.081 compared to USD 0.216 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.77 CAD | +10.00% | +11.59% | +161.02% |
29/05 | NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
25/04 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+161.02% | 3.78Cr | |
+23.13% | 4.69TCr | |
+37.38% | 3.91TCr | |
-8.73% | 3.85TCr | |
+28.09% | 3.1TCr | |
-12.26% | 2.61TCr | |
+10.57% | 2.59TCr | |
+45.05% | 1.42TCr | |
+32.23% | 1.25TCr | |
-6.56% | 1.14TCr |
- Stock Market
- Equities
- NRX Stock
- News NurExone Biologic Inc.
- NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023